Amundi Lowers Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Amundi decreased its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 6.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 406,928 shares of the company’s stock after selling 27,864 shares during the period. Amundi’s holdings in Vaxcyte were worth $32,986,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Whipplewood Advisors LLC purchased a new position in shares of Vaxcyte during the 4th quarter valued at $28,000. Smartleaf Asset Management LLC lifted its stake in Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after purchasing an additional 260 shares in the last quarter. Blue Trust Inc. lifted its stake in Vaxcyte by 100.0% in the 4th quarter. Blue Trust Inc. now owns 742 shares of the company’s stock worth $61,000 after purchasing an additional 371 shares in the last quarter. Assetmark Inc. lifted its stake in Vaxcyte by 77,500.0% in the 4th quarter. Assetmark Inc. now owns 776 shares of the company’s stock worth $64,000 after purchasing an additional 775 shares in the last quarter. Finally, Meeder Asset Management Inc. lifted its stake in Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company’s stock worth $80,000 after purchasing an additional 635 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Vaxcyte Trading Up 4.9 %

Shares of NASDAQ:PCVX opened at $73.24 on Thursday. The company has a market capitalization of $9.43 billion, a price-to-earnings ratio of -15.92 and a beta of 1.02. Vaxcyte, Inc. has a 12 month low of $58.10 and a 12 month high of $121.06. The firm’s 50-day moving average is $82.65 and its 200 day moving average is $94.44.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.14. As a group, equities analysts forecast that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $140.00 price target on shares of Vaxcyte in a research note on Wednesday, February 26th. Guggenheim reiterated a “buy” rating and issued a $160.00 price target on shares of Vaxcyte in a research note on Wednesday. Finally, The Goldman Sachs Group assumed coverage on shares of Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 price target on the stock. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $147.50.

Insider Activity at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total value of $710,240.00. Following the transaction, the chief financial officer now directly owns 109,491 shares in the company, valued at $9,720,610.98. This represents a 6.81 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Teri Loxam sold 6,250 shares of the company’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the transaction, the director now owns 7,175 shares in the company, valued at $610,664.25. This represents a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 54,250 shares of company stock worth $4,550,258. Insiders own 3.10% of the company’s stock.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.